Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03404674 · ClinicalTrials.gov registry record · Phase 1
Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)
A Phase 1 study, sponsored by PATH.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT03404674 is a Phase 1 study that has completed, run by PATH. The registered enrollment target is 50 participants.
The verdict
NCT03404674, a Phase 1 study, has completed, sponsored by PATH.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study will evaluate the safety of a prototype Coli surface antigen 6 (CS6) subunit vaccine (CssBA) alone or in combination with Escherichia coli double mutant heat labile toxin (dmLT) given by intramuscular (IM) injection.
Interventions
- BIOLOGICAL CssBA
- BIOLOGICAL dmLT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-01-16 |
| Est. Completion | 2019-03-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03404674
The ClinicalTrials.gov registry entry for NCT03404674 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PATH, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CssBA is the first listed.
NCT03404674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03404674 about?
NCT03404674 is a clinical study titled "Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)". This study will evaluate the safety of a prototype Coli surface antigen 6 (CS6) subunit vaccine (CssBA) alone or in combination with Escherichia coli double mutant heat labile toxin (dmLT) given by intramuscular (IM) injection.
What is the current status of trial NCT03404674?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2018-01-16. Estimated completion is 2019-03-26.
What interventions are being tested in trial NCT03404674?
The interventions under investigation include: CssBA (BIOLOGICAL), dmLT (BIOLOGICAL).
Who is sponsoring clinical trial NCT03404674?
This trial is sponsored by PATH, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.